GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

The Law Offices of Frank R. Cruz announces an investigation of GSK plc. ("GSK" or the "Company") (NYSE: GSK) on behalf of investors concerning the Company's possible violations of federal securities ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

Banco Santander (BME: SAN) shares spiked over 6% on Wednesday after the lender unveiled plans for €10 billion (£8.3 billion) ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

European shares saw a rise driven by healthcare giants GSK and Novo Nordisk following robust quarterly results. Novo Nordisk's strong profits from its drug Wegovy and GSK's share buyback plan boosted ...